Perrotta F, Nankivell M, Adizie JB, et al. - This large multicenter study was performed to ascertain if samples from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) can be used for programmed death-ligand 1 (PD-L1) testing in non-small cell lung cancer (NSCLC) relative to other methods. They analyzed 577 NSCLC specimens from consecutive patients with NSCLC across six centers in the UK and one in the US between January 2015 and December 2016. The overall percentage of patients with successful PD-L1 testing in the EBUS-TBNA group (189 specimens) was identified as 94.7%. Compared with other methods of tissue acquisition, sampling adequacy did not differ significantly. Overall, findings revealed that EBUS-TBNA afforded adequate samples for PD-L1 testing. High PD-L1 expression was observed in relation to advanced N stage and the presence of brain metastasis.